The one recent study I read showed much larger effect than others, but it was neither single or double blinded.
I looked now and then at new reviews, and they all underscore the potential of manipulating the gut microme to manage UC and/or UC symptoms. But, most UC meds still have markedly higher rates of success.
The quality of the donor, and a personalized match between donor microbiome and the recipient's microbiome deficits seems to be important.
While some GI may be fuzzy on the cutting edge of research (because they are in practice and not academia) it seems premature to expect them to alter the standard of care based on the weight of current research. Important questions remain about
FMT, and questions as to whether other manipulations of gut microbiome might be more promising direction.
You might look at this 2018 review:
Current Evidence for the Management of Inflammatory Bowel Diseases
Using Fecal Microbiota Transplantation said...
Randomized controlled trials (RCTs) and meta-analyses have suggested that FMT may facilitate clinical and endoscopic remission in patients with active ulcerative colitis (UC). ...
... Summary: FMT for patients with IBD is promising as RCTs have shown the benefit of FMT for UC, although the efficacy of FMT for CD is less clear. Further large and well-designed trials are necessary to resolve critical issues such as the donor selection, the ideal route of administration, duration, frequency of FMT, and the long-term sustained efficacy and safety.